A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Bioactive Materials"
DOI: 10.1016/j.bioactmat.2021.10.046
Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as Erlotinib, have demonstrated remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC) patients with mutated EGFR. However, the efficacy of EGFR-TKIs in… read more here.
Keywords: egfr wild; wild type; erlotinib egfr; nanotheranostic agent ... See more keywords